PAHO Director calls for urgent actions to reduce health inequities in the Americas

Cristina Mitchell

28 Sep 2023

The post Fall is about to show us how beautiful letting go can be first appeared on Toronto Caribbean Newspaper.

The Host

Julie Rovner
KFF Health News

@jrovner

Read Julie's stories.

Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A to Z,” now in its third edition.

Federal officials have instructed at least 30 states to reinstate Medicaid and Children’s Health Insurance Program coverage for half a million people, including children, after an errant computer program wrongly determined they were no longer eligible. It’s just the latest hiccup in the yearlong effort to redetermine the eligibility of beneficiaries now that the program’s pandemic-era expansion has expired.

Meanwhile, the federal government is on the verge of a shutdown, as a small band of House Republicans resists even a short-term spending measure to keep the lights on starting Oct. 1. Most of the largest federal health programs, including Medicare, have other sources of funding and would not be dramatically impacted — at least at first. But nearly half of all employees at the Department of Health and Human Services would be furloughed, compromising how just about everything runs there.

This week’s panelists are Julie Rovner of KFF Health News, Rachel Roubein of The Washington Post, Sandhya Raman of CQ Roll Call, and Sarah Karlin-Smith of Pink Sheet.

Panelists

Sarah Karlin-Smith
Pink Sheet

@SarahKarlin

Read Sarah's stories

Sandhya Raman
CQ Roll Call

@SandhyaWrites

Read Sandhya's stories

Rachel Roubein
The Washington Post

@rachel_roubein

Read Rachel's stories

Among the takeaways from this week’s episode:

• Officials in North Carolina announced the state will expand its Medicaid program starting on Dec. 1, granting thousands of low-income residents access to health coverage. With North Carolina’s change, just 10 states remain that have not expanded the program — yet, considering those states have resisted even as the federal government has offered pandemic-era and other incentives, it is unlikely more will follow for the foreseeable future.
• The federal government revealed that nearly half a million individuals — including children — in at least 30 states were wrongly stripped of their health coverage under the Medicaid unwinding. The announcement emphasizes the tight-lipped approach state and federal officials have taken to discussing the in-progress effort, though some Democrats in Congress have not been so hesitant to criticize.
• The White House is pointing to the possible effects of a government shutdown on health programs, including problems enrolling new patients in clinical trials at the National Institutes of Health and conducting food safety inspections at the FDA.
• Americans are grappling with an uptick in covid cases, as the Biden administration announced a new round of free test kits available by mail. But trouble accessing the updated vaccine and questions about masking are illuminating the challenges of responding in the absence of a more organized government effort.
• And the Biden administration is angling to address health costs at the executive level. The White House took its first step last week toward banning medical debt from credit scores, as the Federal Trade Commission filed a lawsuit to target private equity’s involvement in health care.
• Plus, the White House announced the creation of its first Office of Gun Violence Prevention, headed by Vice President Kamala Harris.

Also this week, Rovner interviews KFF Health News’ Samantha Liss, who reported and wrote the latest KFF Health News-NPR “Bill of the Month,” about a hospital bill that followed a deceased patient’s family for more than a year. If you have an outrageous or infuriating medical bill you’d like to send us, you can do that here.

Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too:

Julie Rovner: JAMA Internal Medicine’s “Comparison of Hospital Online Price and Telephone Price for Shoppable Services,” by Merina Thomas, James Flaherty, Jiefei Wang, et al.

Sarah Karlin-Smith: The Los Angeles Times’ “California Workers Who Cut Countertops Are Dying of an Incurable Disease,” by Emily Alpert Reyes and Cindy Carcamo.

Rachel Roubein: KFF Health News’ “A Decades-Long Drop in Teen Births Is Slowing, and Advocates Worry a Reversal Is Coming,” by Catherine Sweeney.

Sandhya Raman: NPR’s “1 in 4 Inmate Deaths Happen in the Same Federal Prison. Why?” by Meg Anderson.

Also mentioned in this week’s episode:

• KFF Health News’ “Diagnosis: Debt,” by Noam N. Levey and KFF Health News, NPR, and CBS staff.
• The New York Times’ “In Hospitals, Viruses Are Everywhere. Masks Are Not,” by Apoorva Mandavilli.

click to open the transcript

Transcript: More Medicaid Messiness

KFF Health News’ ‘What the Health?’Episode Title: More Medicaid MessinessEpisode Number: 316Published: Sept. 27, 2023

[Editor’s note: This transcript was generated using both transcription software and a human’s light touch. It has been edited for style and clarity.]

Julie Rovner: Hello and welcome back to “What the Health?” I’m Julie Rovner, chief Washington correspondent for KFF Health News. And I’m joined by some of the best and smartest health reporters in Washington. We’re taping early this week, on Wednesday, Sept. 27, at 10 a.m. As always, news happens fast and things might’ve changed by the time you hear this, so here we go.

We are joined today via video conference by Rachel Roubein of The Washington Post.

Rachel Roubein: Good morning. Thanks for having me.

Rovner: Sandhya Raman of CQ Roll Call.

Sandhya Raman: Good morning.

Rovner: And Sarah Karlin-Smith of the Pink Sheet.

Sarah Karlin-Smith: Hi, everybody.

Rovner: Later in this episode we’ll have my KFF Health News-NPR “Bill of the Month” interview with Samantha Liss. This month’s bill is literally one that followed a patient to his family after his death. But first, the news. I want to start with Medicaid this week. North Carolina, which approved but didn’t fund its Medicaid expansion earlier this year, approved a budget this week that will launch the expansion starting Dec. 1. That leaves just 10 states that have still not expanded the program to, mostly, low-income adults, since the Affordable Care Act made it possible in, checks notes, 2014. Any other holdout states on the horizon? Florida is a possibility, right, Rachel?

Roubein: Yes. There’s only technically three states that can do ballot measures. Now North Carolina, I believe, was the first state to actually pass through the legislature since Virginia in 2018. A lot of the most recent states, seven conservative-leaning states, instead pursued the ballot measure path. In Florida, advocates have been eyeing a 2026 ballot measure. But the one issue in Florida is that they need a 60% threshold to pass any constitutional amendment, so that is pretty, pretty high and would take a lot of voter support.

Rovner: And they would need a constitutional amendment to expand Medicaid?

Roubein: A lot of the states have been going the constitutional amendment route in terms of Medicaid in recent years. Because what they found was some legislatures would come back and try and change it, but if it’s a constitutional amendment, they weren’t able to do that. But a lot of the holdout states don’t have ballot measure processes, where they could do this — like Alabama, Georgia, etc.

Raman: Kind of just echoing Rachel that this one has been interesting just because it had come through the legislature. And even with North Carolina, it’s been something that we’ve been eyeing for a few years, and that they’d gone a little bit of the way, a little bit of the way a few times. And it was kind of the kind of gettable one within the ones that hadn’t expanded. And the ones we have left, there’s just really not been much progress at all.

Rovner: I would say North Carolina, like Virginia, had a Democratic governor that ran on this and a Republican legislature, or a largely Republican legislature, hence the continuing standoff. It took both states a long time to get to where they had been trying to go. And you’re saying the rest of the states are not split like that?

Raman: Yeah, I think it’ll be a much more difficult hill to climb, especially when, in the past, we had more incentives to expand with some of the previous covid relief laws, and they still didn’t bite. So it’s going to be more difficult to get those.

Rovner: No one’s holding their breath for Texas to expand. Anyway, while North Carolina will soon start adding people to its Medicaid rolls, the rest of the states are shedding enrollees who gained coverage during the pandemic but may no longer be eligible. And that unwinding has been bumpy to say the least. The latest bump came last week when the Department of Health and Human Services revealed that more than half a million people, mostly children, had their coverage wrongly terminated by as many as 30 states. It seems a computer program failed to note that even if a parent’s income was now too high to qualify, that same income could still leave their children eligible. Yet the entire family was being kicked off because of the way the structure of the program worked. I think the big question here is not that this happened, but that it wasn’t noticed sooner. It should have been obvious — children’s eligibility for Medicaid has been higher than adults since at least the 1980s. This unwinding has been going on since this spring. How is this only being discovered now? It’s September. It’s the end of September.

Roubein: Yeah. I mean, this was something advocates who have been closely watching this have been ringing the alarm bells for a while, and then it took time. CMS [the Centers for Medicare & Medicaid Services] had put something out, I believe it was roughly two weeks before they actually then had the roughly half a million children regain coverage — they had put out a, “OK, well, we’re exploring which states.” And lots of reporters were like, “OK, well which state is this an issue?” So yeah, the process seemed like it took some time here.

Rovner: I know CMS has been super careful. I mean, I think they’re trying not to politicize this, because they’ve been very careful not to name states, and in many cases who they know have been wrongly dropping people. I guess they’re trying to keep it as apolitical as possible, but I think there are now some advocates who worry that maybe CMS is being a little too cautious.

Karlin-Smith: Yeah, I think from the other side too, if you’ve talked to state officials, they’re also trying to be really cautious and not criticize CMS. So it seems like both sides are not wanting to go there. But I mean some Democrats in Congress have been critical of how the effort has gone.

Rovner: Yeah. And of course, if the government shuts down, as seems likely at the end of this week, that’s not going to make this whole process any easier, right? The states will still get to do what the states are doing. Their shutdown efforts, or their re-qualification efforts, are not federally funded, but the people at CMS are.

Karlin-Smith: Yeah, that’ll just throw another thorn in this as we’re getting very, very likely headed towards a shutdown at this point on the 27th. So I think that’ll be another barrier for them regardless. And I mean, most CMS money isn’t even affected by the yearly budget anyways because it’s mandatory funding, but that’ll be a barrier for sure.

Rovner: So, speaking of the government shutdown, it still seems more likely than not that Congress will fail to pass either any of the 12 regular spending bills or a temporary measure to keep the lights on when the fiscal year ends at midnight Sunday. That would lead to the biggest federal shutdown since 2013 when, fun fact, the shutdown was an attempt to delay the rollout of the Affordable Care Act. What happens to health programs if the government closes? It’s kind of a big confusing mess, isn’t it?

Roubein: Yeah, well, what we know that would definitely continue and in the short term is Medicare and Medicaid, Obamacare’s federal insurance marketplace. Medicaid has funding for at least the next three months, and there’s research developing vaccines and therapeutics that HHS, they put out their kind of contingency “What happens if there’s a shutdown?” plan. But there’s some things that the White House and others are kind of trying to point to that would be impacted, like the National Institutes of Health may not be able to enroll new patients in clinical trials, the FDA may need to delay some food safety inspections, etc.

Rovner: Sarah, I actually forgot because, also fun fact, the FDA is not funded through the rest of the spending bill that includes the Department of Health and Human Services. It’s funded through the agriculture bill. So even though HHS wasn’t part of the last shutdown in 2018 and 2019, because the HHS funding bill had already gone through, the FDA was sort of involved, right?

Karlin-Smith: Right. So FDA is lumped with the USDA, the Agriculture Department, for the purposes of congressional funding, which is always fun for a health reporter who has to follow both of those bills. But FDA is always kind of a unique one with shutdown, because so much of their funding now is user fees, particularly for specific sections. So the tobacco part of FDA is almost 100% funded by user fees, so they’re not really impacted by a shutdown. Similarly, a lot of drug, medical device applications, and so forth also are totally funded by user fees, so their reviews keep going. That said, the way user fees are, they’re really designated to specific activities.

So, where there isn’t user fees and it’s not considered a critical kind of public health threat, things do shut down, like Rachel mentioned: a lot of food work and inspections, and even on the drug and medical device side, some activities that are related that you might think would continue don’t get funded.

Rovner: Sandhya, is there any possibility that this won’t happen? And that if it does happen, that it will get resolved anytime soon?

Raman: At this point, I don’t think that we can navigate it. So last night, the Senate put out their bipartisan proposal for a continuing resolution that you would attach as an amendment to the FAA, the Federal Aviation [Administration] reauthorization. And so that would temporarily extend a lot of the health programs through Nov. 17. The issue is that it’s not something that if they are able to pass that this week, they’d still have to go to the House. And the House has been pretty adamant that they want their own plan and that the CR that they were interested in had a lot more immigration measures, and things there.

And the House right now has been busy attempting to pass this week four of the 12 appropriations bills. And even if they finished the four that they did, that they have on their plate, that would still mean going to the Senate. And Biden has said he would veto those, and it’s still not the 12. So at this point, it is almost impossible for us to not at least see something short-term. But whether or not that’s long-term is I think a question mark in all the folks that I have been talking to about this right now.

Rovner: Yeah, we will know soon enough what’s going to happen. Well, meanwhile, because there’s not enough already going on, covid is back. Well, that depends how you define back. But there’s a lot more covid going around than there was, enough so that the federal government has announced a new round of free tests by mail. And there’s an updated covid vaccine — I think we’re not supposed to call it a booster — but its rollout has been bumpy. And this time it’s not the government’s fault. That’s because this year the vaccine is being distributed and paid for by mostly private insurance. And while lots of people probably won’t bother to get vaccinated this fall, the people who do want the vaccine are having trouble getting it. What’s happening? And how were insurers and providers not ready for this? We’d been hearing the updated vaccines would be available in mid-September for months, Sarah. I mean they really literally weren’t ready.

Karlin-Smith: Yeah. I mean, it’s not really clear why they weren’t ready, other than perhaps they felt they didn’t need to be, to some degree. I mean, normally, I know I was reading actually because we’ve also recently gotten RSV [respiratory syncytial virus] vaccine approvals — normally they actually have almost like a year, I think, to kind of add vaccines to plans and schedules and so forth, and pandemic covid-related laws really shortened the time for covid. So they should have been prepared and ready. They knew this was coming. And people are going to pharmacies, or going to a doctor’s appointment, and they’re being told, “Well, we can give you the vaccine, but your insurance plan isn’t set up to cover it yet, even though technically you should be.” There seems like there’s also been lots of distribution issues where again, people are going to sites where they booked appointments, and they’re saying, “Oh, actually we ran out.” They’re trying another site. They’ve run out.

So, it’s sort of giving people a sense of the difference of what happens when sort of the government shepherds an effort and everybody — things are a bit simplified, because you don’t have to think about which site does your insurance cover. There is a program for people who don’t have insurance now who can get the vaccine for free, but again, you’re more limited in where you can go. There’s not these big free clinics; that’s really impacting childhood vaccinations, because, again, a lot of children can’t get vaccinated at the pharmacy. So I think people are being reminded of what normal looked like pre-covid, and they’re realizing maybe we didn’t like this so much after all.

Rovner: Yeah, it’s not so efficient either. All the people who said, “Oh, the private sector could do this so much more efficiently than the government.” And it’s like, we’re ending up with pretty much the same issues, which is the people who really want the vaccine are chasing around and not finding it. And I know HHS Secretary Becerra went and had this event at a D.C. pharmacy where he was going to get his vaccine. And I think the event was intended to encourage people to go get vaccinated, but it happened right at the time when the big front surge of people who wanted to get vaccinated couldn’t find the vaccine.

Karlin-Smith: I think that’s a big concern because we’ve had such low uptake of booster or additional covid shots over the past couple of years. So the people who are sort of the most go-getters, the ones who really want the shots, are having trouble and feeling a bit defeated. What does that mean for the people that are less motivated to get it, who may not make a second or third attempt if it’s not easy? We sort of know, and I think public health folks kind of beat the drum, that sort of just meeting people where they are, making it easy, easy, easy, is really how you get these things done. So it’s hard to see how we can improve uptake this year when it’s become more complicated, which I think is going to be a big problem moving forward.

Rovner: Yeah. Right. And clearly these are issues that will be ironed out probably in the next couple of weeks. But I think what people are going to remember, who are less motivated to go get their vaccines, is, “Oh my God, these people I know tried to get it and it took them weeks. And they showed up for their appointment and they couldn’t get it.” And it’s like, “It was just too much trouble and I can’t deal with it.” And there’s also, I think you mentioned that there’s an issue with kids who are too young to get the vaccine too, right?

Karlin-Smith: Right. Still, I think people forget that you have to be 6 months to get the vaccine. If you’re under 3, you basically cannot get it in a pharmacy, so you have to get it in a doctor’s office. But a lot of people are reporting online their doctor’s office sort of stopped providing covid vaccines. So they’re having trouble just finding where to go. It seems like the distribution of shots for younger children has also been a bit slower as well. And again, this is a population where just even primary series uptake has been a problem. And people are in this weird gap now where, if you can’t get access to the new covid vaccine but your kid is eligible, the old vaccine isn’t available.

So you’re sort of in this gap where your kid might not have had any opportunity yet to get a covid vaccine, and there’s nothing for them. I think we forget sometimes that there are lots of groups of people that are still very vulnerable to this virus — including newborn babies who haven’t been exposed at all, and haven’t gotten a chance to get vaccinated.

Rovner: Yeah. So this is obviously still something that we need to continue to look at. Well, meanwhile, mask mandates are making a comeback, albeit a very small one. And they are not going over well. I’ve personally been wearing a mask lately because I’m traveling later this week and next, and don’t want to get sick, at least not in advance. But masks are, if anything, even more controversial and political than they were during the height of the pandemic. Does public health have any ideas that could help reverse that trend? Or are there any other things we could do? I’ve seen some plaintiff complaints that we’ve not done enough about ventilation. That could be something where it could help, even if people won’t or don’t want to wear masks. I mean, I’m surprised that vaccination is still pretty much our only defense.

Karlin-Smith: I think with masks, one thing that’s made it hard for different parts of the health system and lower-level kind of state public health departments to deal with masks is that the CDC [Centers for Disease Control and Prevention] recommendations around masking are pretty loose at this point. So The New York Times had a good article about hospitals and masking, and the kind of guidance around triggers they’ve given them are so vague. They kind of are left to make their own decisions. The CDC actually still really hasn’t emphasized the value of KN95 and N95 respirators over surgical masks. So I think it becomes really hard for those lower-level institutions to sort of push for something that is kind of controversial politically. And a lot of people are just tired of it when they don’t have the support of those bigger institutions saying it. And some of just even figuring out levels of the virus and when that should trigger masking.

It’s much harder to track nowadays because so much of our systems and data reporting is off. So, we have this sense we’re in somewhat of a surge now. Hospitalizations are up and so forth. But again, it’s a lot easier for people to make these decisions and figure out when to pull triggers when you have clear data that says, “This is what’s going on now.” And to some extent we’re … again, there’s a lot of evidence that points to a lot of covid going around now, but we don’t have that sort of hard data that makes it a lot easier for people to justify policy choices.

Raman: You just brought up ventilation and it took time, one, for some scientists to realize that covid is also spread through ultra-tiny particles. But it also took, after that, a while for the White House to pivot its strategy to stress ventilation measures in addition to masks, and face covering. So a lot of places are still kind of behind on having better ventilation in an office, or kind of wherever you’re going.

Rovner: Yeah, I mean, one would think that improving ventilation in schools would improve, not only not spreading covid, but not spreading all of the respiratory viruses that keep kids out of school and that make everybody sick during the winter, during the school year.

Roubein: I was going to piggyback on something Sarah said, which was about how the CDC doesn’t have clear benchmarks on when there should be a guideline for what is high transmission in the hospital for them to reinstate a mask mandate or whatever. But there’s also nuance to consider there. Within that there’s, is there a partial masking rule? Which is like: Does the health care staff have to wear them versus the patients? And does that have enough benefit on its own if it’s only required to one versus the other? I mean, I know that a lot of folks have called for more strict rules with that, but then there’s also the folks that are worried about the backlashes. This has gotten so politicized, how many different medical providers have talked about angst at them, attacks at them, over the polarization of covid? So there’s so many things that are intertwined there that it’s tough to institute something.

Karlin-Smith: I think the other thing is we keep forgetting this is not all about covid. We’ve learned a lot of lessons about public health that could be applicable, like you mentioned in schools, beyond covid. So if you’re in the emergency room, because you have cancer and you need to see a doctor right away. And you’re sitting next to somebody with RSV or the flu, it would also be beneficial to have that patient wearing a mask because if you have cancer, you do not need to add one of these infectious diseases on top of it. So it’s just been interesting, I think, for me to watch because it seemed like at different points in this crisis, we were sort of learning things beyond covid for how it could improve our health care system and public health. But for the most part, it seems like we’ve just kind of gone back to the old ways without really thinking about what we could incorporate from this crisis that would be beneficial in the future.

Rovner: I feel like we’ve lost the “public” in public health. That everybody is sort of, it’s every individual for him or herself and the heck with everybody else. Which is exactly the opposite of how public health is supposed to work. But perhaps we will bounce back. Well, moving on. The Biden administration, via the Consumer Financial Protection Bureau, the CFPB, took the first steps last week to ban medical debt from credit scores, which would be a huge step for potentially tens of millions of Americans whose credit scores are currently affected by medical debt. Last year, the three major credit bureaus, Equifax, Experian, and TransUnion, agreed not to include medical debt that had been paid off, or was under $500 on their credit reports. But that still leaves lots and lots of people with depressed scores that make it more expensive for them to buy houses, or rent an apartment, or even in some cases to get a job. This is a really big deal if medical debt is going to be removed from people’s credit reports, isn’t it?

Roubein: Yeah. I think that was an interesting move when they announced that this week. Because the CFPB had mentioned that in a report they did last year, 20% of Americans have said that they had medical debt. And it doesn’t necessarily appear on all credit reports, but like you said, it can. And having that financial stress while going through a health crisis, or someone in your family going through a health crisis, is layers upon layers of difficulty. And they had also said in their report that medical billing data is not an accurate indicator of whether or not you’ll repay that debt compared to other types of credit. And it also has the layers of insurance disputes, and medical billing errors, and all that sort of thing. So this proposal that they have ends up being finalized as a rule, it could be a big deal. Because some states have been trying to do this on a state-by-state level, but still in pretty early stages in terms of a lot of states being on board. So this can be a big thing for a fifth of people.

Rovner: Yeah, many people. I’m going to give a shout-out here to my KFF Health News colleague Noam Levey, who’s done an amazing project on all of this, and I think helped sort of push this along. Well, while we are on the subject of the Biden administration and money in health care, the Federal Trade Commission is suing a private equity-backed doctors group, U.S. Anesthesia Partners, charging anti-competitive behavior, that it’s driving up the price of anesthesia services by consolidating all the big anesthesiology practices in Texas, among other things. FTC Chair Lina Khan said the agency “will continue to scrutinize and challenge serial acquisitions roll-ups and other stealth consolidation schemes that unlawfully undermine fair competition and harm the American public.” This case is also significant because the FTC is suing not just the anesthesia company, but the private equity firm that backs it, Welsh, Carson, Anderson & Stowe, which is one of the big private equity firms in health care. Is this the shot across the bow for private equity and health care that a lot of people have been waiting for? I mean, we’ve been talking about private equity and health care for three or four years now.

Karlin-Smith: I think that’s what the FTC is hoping for. They’re saying not just that we’re going after anti-competitive practices in health care, that, I think, they’re making a clear statement that they’re going after this particular type of funder, which we’ve seen has proliferated around the system. And I think this week there was a report from the government showing that CMS can’t even track all of the private equity ownership of nursing homes. So we know this isn’t the only place where doctors’ practices being bought up by private equity has been seen as potentially problematic. So this has been a very sort of activist, I think, aggressive FTC in health care in general, and in a number of different sectors. So I think they’re ready to deliberate, with their actions and warnings.

Rovner: Yeah, it’s interesting. I mean, we mostly think, those of us who have followed the FTC in healthcare, which gets pretty nerdy right there, usually think of big hospital groups trying to consolidate, or insurers trying to consolidate these huge mega-mergers. But what’s been happening a lot is these private equity companies have come in and bought up physician practices. And therefore they become the only providers of anesthesia, or the only providers of emergency care, or the only providers of kidney dialysis, or the only providers of nursing homes, and therefore they can set the prices. And those are not the level of deals that tend to come before the FTC. So I feel like this is the FTC saying, “See you little people that are doing big things, we’re coming for you too.” Do we think this might dampen private equity’s enthusiasm? Or is this just going to be a long-drawn-out struggle?

Roubein: I could see it being more of a long-drawn-out struggle because even if they’re showing it as an example, there’s just so many ways that this has been done in so many kind of sectors as you’ve seen. So I think it remains to be seen further down the line as this might happen in a few different ways to a few different folks, and how that kind of plays out there. But it might take some time to get to that stage.

Karlin-Smith: I was going to say it’s always worth also thinking about just the size and budget of the FTC in comparison to the amount of private actors like this throughout the health system. So I mean, I think that’s one reason sometimes why they do try and kind of use that grandstanding symbolic messaging, because they can’t go after every bad actor through that formal process. So they have to do the signaling in different ways.

Raman: I think probably as we’ve all learned as health reporters, it takes a really long time for there to be change in the health care system.

Rovner: And I was just going to say, one thing we know about people who are in health care to make money is that they are very creative in finding ways to do it. So whatever the rules are, they’re going to find ways around them and we will just sort of keep playing this cat and mouse for a while. All right, well finally this week, a story that probably should have gotten more attention. The White House last week announced creation of the first-ever Office of Gun Violence Prevention to be headed by Vice President Kamala Harris. Its role will be to help implement the very limited gun regulation passed by Congress in 2022, and to coordinate other administration efforts to curb gun violence. I know that this is mostly for show, but sometimes don’t you really have to elevate an issue like this to get people to pay attention, to point out that maybe you’re trying to do something? Talk about things that have been hard for the government to do over the last couple of decades.

Raman: It took Congress a long time to then pass a new gun package, which the shooting in Uvalde last year ended up catalyzing. And Congress actually got something done, which was more limited than some gun safety advocates wanted. But it does take a lot to get gun safety reform across the finish line.

Rovner: I know. I mean, it’s one of those issues that the public really, really seems to care about, and that the government really, really, really has trouble doing. I’ve been covering this so long, I remember when they first banned gun violence research at HHS back in the mid-1990s. That’s how far back I go, that they were actually doing it. And the gun lobby said, “No, no, no, no, no. We don’t really want these studies that say that if you have a gun in the house, it’s more likely to injure somebody, and not necessarily the bad guy.” They were very unhappy, and it took until three or four years ago for that to be allowed to be funded. So maybe the idea that they’re elevating this somewhat, to at least wave to the public and say, “We’re trying. We’re fighting hard. We’re not getting very far, but we’re definitely trying.” So I guess we will see how that comes out.

All right, well that is this week’s news. Now, we will play my “Bill of the Month” interview with Sam Liss, and then we’ll come back with our extra credits. I am pleased to welcome to the podcast my KFF Health News colleague Samantha Liss, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” installment. Welcome.

Liss: Hi.

Rovner: This month’s bill involves a patient who died in the hospital, right? Tell them who he was, what he was sick with, and about his family.

Liss: Yeah. So Kent Reynolds died after a lengthy hospital stay in February of 2022. He was actually discharged after complications from colon cancer, and died in his home. And his widow, Eloise Reynolds, was left with a series of complicated hospital bills, and she reached out to us seeking help after she couldn’t figure them out. And her and Kent were married for just shy of 34 years. They lived outside of St. Louis and they have two adult kids.

Rovner: So Eloise Reynolds received what she assumed was the final hospital bill after her husband died, which she paid, right?

Liss: Yeah, she did. She paid what she thought was the final bill for $823, but a year later she received another bill for $1,100. And she was confused as to why she owed it. And no one could really give her a sufficient answer when she reached out to the hospital system, or the insurance company.

Rovner: Can a hospital even send you a bill a year after you’ve already paid them?

Liss: You know what, after looking into this, we learned that yeah, they actually can. There’s not much in the way that stops them from coming after you, demanding more money, months, or even years later.

Rovner: So this was obviously part of a dispute between the insurance company and the hospital. What became of the second bill, the year-later bill?

Liss: Yeah. After Eloise Reynolds took out a yardstick and went line by line through each charge and she couldn’t find a discrepancy or anything that had changed, she reached out to KFF Health News for help. And she was still skeptical about the bill and didn’t want to pay it. And so when we reached out to the health system, they said, “Actually, you know what? This is a clerical error. She does not owe this money.” And it sort of left her even more frustrated, because as she explained to us, she says, “I think a lot of people would’ve ended up paying this additional amount.”

Rovner: So what’s the takeaway here? What do you do if you suddenly get a bill that comes, what seems, out of nowhere?

Liss: The experts we talked to said Eloise did everything right. She was skeptical. She compared, most importantly, the bills that she was getting from the hospital system against the EOBs that she was getting from her insurance company.

Rovner: The explanation of benefits form.

Liss: That’s right. The explanation of benefits. And she was comparing those two against one another, to help guide her on what she should be doing. And because those were different between the two of them, she was left even more confused. I think folks that we spoke to said, “Yeah, she did the right thing by pushing back and demanding some explanations.”

Rovner: So I guess the ultimate lesson here is, if you can’t get satisfaction, you can always write to us.

Liss: Yeah, I hate to say that in a way, because that’s a hard solution to scale for most folks. But yeah, I mean, I think it points to just how confusing our health care system is. Eloise seemed to be a pretty savvy health care consumer, and she even couldn’t figure it out. And she was pretty tenacious in her pursuit of making phone calls to both the insurance company and the hospital system. And I think when she couldn’t figure that out, and she finally turned to us asking for help.

Rovner: So well, another lesson learned. Samantha Liss, thank you very much for joining us.

Liss: Thanks.

Rovner: Hey, “What the Health?” listeners, you already know that few things in health care are ever simple. So, if you like our show, I recommend you also listen to “Tradeoffs,” a podcast that goes even deeper into our costly, complicated, and often counterintuitive health care system. Hosted by longtime health care journalist and friend Dan Gorenstein, “Tradeoffs” digs into the evidence and research data behind health care policies and tells the stories of real people impacted by decisions made in C-suites, doctors’ offices, and even Congress. Subscribe wherever you listen to your podcasts.

OK, we’re back. It’s time for our extra-credit segment. That’s when we each recommend a story we read this week we think you should read too. As always, don’t worry if you miss it. We will post the links on the podcast page at kffhealthnews.org, and in our show notes on your phone or other mobile device. Sarah, you were the first to choose this week, so you get to go first.

Karlin-Smith: Sure. I looked at a story in the Los Angeles Times, “California Workers Who Cut Countertops Are Dying of an Incurable Disease,” by Emily Alpert Reyes and Cindy Carcamo. Hopefully I didn’t mispronounce her name. They wrote a really fascinating but sad story about people working in an industry where they’re cutting engineered stone countertops for people’s kitchens and so forth. And because of the materials in this engineered product, they’re inhaling particles that is basically giving people at a very young age incurable and deadly lung disease. And it’s an interesting public health story about sort of the lack of protection in place for some of the most vulnerable workers. It seems like this industry is often comprised of immigrant workers. Some who kind of essentially go to … outside a Home Depot, the story suggests, or something like that and kind of get hired for day labor.

So they just don’t have the kind of power to sort of advocate for protections for themselves. And it’s just also an interesting story to think about, as consumers I think people are not always aware of the costs of the products they’re choosing. And how that then translates back into labor, and the health of the people producing it. So, really fascinating, sad piece.

Rovner: Another product that you have to sort of … I remember when they first were having the stories about the dust in microwave popcorn injuring people. Sandhya, why don’t you go next?

Raman: So my extra credit this week is from NPR and it’s by Meg Anderson. And it’s called “1 in 4 Inmate Deaths Happen in the Same Federal Prison. Why?” This is really interesting. It’s an investigation that looks at the deaths of individuals who died either while serving in federal prison or right after. And they looked at some of the Bureau of Prisons data, and it showed that 4,950 people had died in custody over the past decade. But more than a quarter of them were all in one correctional facility in Butner, North Carolina. And the investigation found out that the patients here and nationwide are dying at a higher rate, and the incarcerated folks are not getting care for serious illnesses — or very delayed care, until it’s too late. And the Butner facility has a medical center, but a lot of times the inmates are being transferred there when it was already too late. And then it’s really sad the number of deaths is just increasing. And just, what can be done to alleviate them?

Rovner: It was a really interesting story. Rachel.

Roubein: My extra credit, the headline is “A Decades-Long Drop in Teen Births Is Slowing, and Advocates Worry a Reversal Is Coming,” by Catherine Sweeney from WPLN, in partnership with KFF Health News. And she writes about the national teen birth rate and how it’s declined dramatically over the past three decades. And that, essentially, it’s still dropping, but preliminary data released in June from the CDC shows that that descent may be slowing. And Catherine had talked to doctors and other service providers and advocates, who essentially expressed concern that the full CDC dataset release later this year can show a rise in teen births, particularly in Southern states. And she talked to experts who pointed to several factors here, including the Supreme Court’s decision to overturn Roe v. Wade, intensifying political pushback against sex education programs, and the impact of the pandemic on youth mental health.

Rovner: Yeah. There’ve been so many stories about the decline in teen birth, which seemed mostly attributable to them being able to get contraception. To get teens not to have sex was less successful than getting teens to have safer sex. So we’ll see if that tide is turning. Well, I’m still on the subject of health costs this week. My story is a study from JAMA Internal Medicine that was conducted in part by Shark Tank panelist Mark Cuban, for whom health price transparency has become something of a crusade. This study is of a representative sample of 60 hospitals of different types conducted by researchers from the University of Texas. And it assessed whether the online prices posted for two common procedures, vaginal childbirth and a brain MRI, were the same as the prices given when a consumer called to ask what the price would be. And surprise. Mostly they were not. And often the differences were very large. In fact, to quote from the study, “For vaginal childbirth, there were five hospitals with online prices that were greater than $20,000, but telephone prices of less than $10,000. The survey was done in the summer of 2022, which was a year and a half after hospitals were required to post their prices online.” At some point, you have to wonder if anything is going to work to help patients sort out the prices that they are being charged for their health care. Really eye-opening study.

All right, that is our show for this week. As always, if you enjoy the podcast, you can subscribe wherever you get your podcasts. We’d appreciate it if you left us a review; that helps other people find us, too. Special thanks as always to our amazing engineer, Francis Ying. Also, as always, you can email us your comments or questions. We’re at whatthehealth@kff.org. Or you can still find me at X, @jrovner. Sarah.

Karlin-Smith: I’m @SarahKarlin, or @sarahkarlin-smith.

Rovner: Sandhya.

Raman: @SandhyaWrites

Rovner: Rachel.

Roubein: @rachel_roubein

Rovner: We will be back in your feed next week. Until then, be healthy.

Credits

Francis Ying
Audio producer

Emmarie Huetteman
Editor

To hear all our podcasts, click here.

And subscribe to KFF Health News’ “What the Health?” on Spotify, Apple Podcasts, Pocket Casts, or wherever you listen to podcasts.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

MAKING A commitment to promote public awareness of the high incidence of prostate cancer among Jamaican men, Guardian Life Limited has donated $1.5 million to the Jamaica Cancer Society (JCS) to aid in screenings for the disease. Renewing its four-...

Health ministers agree on new policy to prevent and control noncommunicable diseases in children, adolescents, and young people

Cristina Mitchell

26 Sep 2023

These drug samples which are declared not of standard quality include Misoprostol Tablets I.P. 200 mcg manufactured by Synokem Pharmaceuticals, Cefotaxime for Injection IP 500 mg manufactured by Maan Pharmaceuticals, Telmisartan, and Chlorthalidone Tablets manufactured by Pure & Cure Healthcare, Paracetamol 120 mg plus Chlorpheniramine Maleate 2 mg/ 5 ml syrup (COLD OUT) manufactured by Fourrts (India) Laboratories and others.

Apart from this, the list further includes popular diabetes drug combination Metformin Hydrochloride Prolonged Release and Glimepiride Tablets IP (GLIMESTAR M2 FORTE) manufactured by Mankind Pharma and AMTAS PRP (Amlodipine and Perindopril Tablets) manufactured by Intas Pharmaceuticals.

This came after analysis and tests conducted by the CDSCO Drugs Control Department on 1166 samples. Out of these, 1118 samples were found to be of standard quality while 48 of them were declared as Not of Standard Quality (NSQ).

A few of the reasons why the drug samples tested failed were the failure of the assay, failure of the dissolution test, failure of the disintegration test, failure of the sterility test, etc.

The samples collected were tested in five laboratories, namely CDL Kolkata, CDTL Chennai, CDTL Mumbai, RDTL Chandigarh, and RDTL Guwahati.

List of Drugs, Medical Devices, and Cosmetics declared as Not of Standard Quality/Spurious/Adulterated/Misbranded for the Month of AUGUST – 2023

List of Drugs, Medical Devices and Cosmetics declared as Not of Standard Quality/Spurious/Adulterated/Misbranded for the Month of

AUGUST – 2023

Total number of samples tested

1166

Total number of samples declared as of Standard Quality

1118

Total number of samples declared as Not of Standard Quality

48

Total number of samples declared as Spurious

00

Total number of samples declared as Misbranded

00

S.No

Name of Drugs/medical device/cosmetics

Batch No.

Date of Manufa cture

Date of Expiry

Manufactured By

Reason for failure

Drawn By

From

1

MOL-PCB Syrup (Paracetamol, Bromhexine Hydrobromide Chlorpheniramine Maleate, Phenylephrine

Hydrochloride, Menthol Syrup) – 60 ml

L22541

03/2023

02/202

5

Aan Pharma Private Limited, 816/1, Pramukh Ind. Estate, Rakanpur 382 721, Ta. Kalol Dist. Gandhinagar (Guj.) India

pH, Assay of Bromhexine Hydrobromide and Phenylephrine Hydrochloride

CDSCO,

Ahmedaba d

CDL

Kolkata

2

Nifedipine Sustain Release Tablets I.P. 20 mg

T230307

03/2023

02/202

5

Medisky Pharmaceuticals Pvt. Ltd., Plot No. 260, GIDC, Talod – 383 215, Sabarkantha, Gujarat

Dissolution

CDSCO,

Ahmedaba d

CDL

Kolkata

3

DICLOGLOBE 50

(Diclofenac Sodium Tablets

I.P. 50 mg)

GT23026

01/2023

12/202

5

Globela Pharma Pvt. Ltd., 357, 358, G.I.D.C. Sachin,

Surat- 394 230, Gujarat, India

Disintegration

CDSCO,

Ahmedaba d

CDL

Kolkata

4

Trimax Expectorant (Terbutaline Sulphate with BromhexineHCl& Guaiphenesin),

23009

01/2023

10/202

4

Norris Medicines Limited, Plot No. 901/3-5, G.I.D.C. Estate,

Ankleshwar – 393 002 (Gujarat).

Assay of Bromhexine Hydrochloride &Menthol.This sample is found to contain 0.118% w/v of Ethylene Glycol and this sample does

not give positive test for Diethylene Glycol

CDSCO,

Ahmedaba d

CDL

Kolkata

5

Frusemide Injection IP (2ml)

AI22236

08/2022

07/202

4

Alves Healthcare Private Limited, NangalUperla, Swarghat Road, Nalagarh, Dist. Solan, Himachal Pradesh - 174101

pH

CDSCO,

Ahmedaba d

CDL

Kolkata

6

Refined Glycerin CP Grade

21100637

10/2021

09/202

5

Adani Wilmar, Pitampura, New Delhi – 110 034

Assay of Glycerin.Thi sample is found to contain 0.025% w/w of Ethylene Glycol and does not give positive result for

Diethylene Glycol

CDSCO,

Ahmedaba d

CDL

Kolkata

7

Sterile Noradrenaline Concentrate IP (2mg /1ml)

INABB23 01

04/2023

03/202

5

Samarth Life Sciences Pvt. Ltd., Unit II: Plot No.2, Industrial Area, Lodhimajra, Baddi, H.P. 173205, India

Description & Particulate Matter

CDSCO,

Ahmedaba d

CDL

Kolkata

8

CyproheptadineHCl with Tricholine Citrate Syrup (Sylpro Plus Syrup)

33002

05/2023

04/202

5

Norris Medicines Limited, Plot No. 801/P, 901/4-5, G.I.D.C.

Estate, Ankleshwar – 393 002 (Gujarat).

Assay of TricholineCitrate.This sample is found to contain Diethylene Glycol 0.243%w/v and Ethylene Glycol

0.171%w/v

CDSCO,

Ahmedaba d

CDL

Kolkata

9

Sibolone (Tibolone Tablets IP)

PLSB230 1

02/2023

09/202

5

Phaarmasia Ltd., Unit – II, Plot No. 145, Phase V, IDA, Jeedimetla (V), Qutubullapur (M), MedchalMalkajgiri (Dist.) 500 055

Dissolution

CDSCO,

Hyderabad

CDL

Kolkata

10

Methylprednisolone Sodium Succinate for Injection USP 40mg

22MS03

11/2022

10/202

4

SAI Parenterals Limited, D1 & D4, Survey No.280, Phase- V, IDA, Jeedimetla, Hyderabad- 500055, Telangana, India.

Uniformity of Dosage Units, Loss on Drying & Assay of Methylprednisolone Sodium Succinate

CDSCO,

Hyderabad

CDL

Kolkata

11

Misoprostol Tablets I.P. 200 mcg

22S1GTA

026

01/2022

12/202

3

Synokem Pharmaceuticals Ltd., Plot No.35-36, Sector- 6A, I.I.E (SIDCUL), Ranipur

(BHEL), Haridwar- 249403, Uttarakhand.

Assay

CDSCO

Bangalore

CDL

Kolkata

12

Cefotaxime for Injection IP 500 mg

CD22002

03/2022

02/202

4

Maan Pharmaceuticals Ltd., Plot-1, G.I.D.C., Phase II,

Modhera Road, Mehsana – 384 002, Gujarat, India

Particulate Matter & Clarity of Solution

CDSCO

Bangalore

CDL

Kolkata

13

Bacillus Clausii Spores Suspension (EbaniproSuspension)

AFL2258 8

08/2022

07/202

4

Aarmed Formulation Pvt. Ltd., Survey No. 431/2, Plot No.1, Steel Town, Moraiya, Tal. Sanand, Distt.

Ahmedabad (Gujarat)

Purity & Specified Pathogen (Pseudomonas aeruginosa)

Drug Control Departmen t Jammu & Kashmir

CDL

Kolkata

14

(Absorbable Surgical Suture

U.S.P (synthetic) 70 cm), (Monofilament Poliglecaprone 25) (STERGIC)

TV22212 7

09/2022

08/202

5

Sugii Surgical India Pvt. Ltd., No.3, Old No. 49/51, 8th Main, Peenya 2nd Stage, Bengaluru – 560058

Diameter

CDSCO

Bangalore

CDL

Kolkata

15

Erythromycin Stearate Tablets IP 250 mg

AT23118

04/2023

03/202

5

Alves Healthcare Private Limited, Village: NangalUperla, Swarghat Road, Tehsil, Nalagarh, Distt. Solan - 174101 (H.P.), India

Dissolution

CDSCO,

South Zone Chennai

CDL

Kolkata

16

Selamer-400 Tablets (Sevelamer Carbonate Tablets 400 mg)

MT22612 4B

12/2022

11/202

4

Mascot Health Series Pvt. Ltd, Plot No.79, 80, Sec-6A, IIE, Sidcul, Haridwar – 249 403, Uttarakhand, India.

Description

CDSCO,

South Zone Chennai

CDL

Kolkata

17

Telmisartan and Chlorthalidone Tablets

PF8C006

09/2022

08/202

4

Pure & Cure Healthcare Pvt. Ltd., Plot No. 26A, 27-30, Sector-8A, I.I.E., SIDCUL,

Ranipur Haridwar – 249 403, Uttarakhand

Dissolution of Chlorthalidone

CDSCO

East Zone Kolkata

CDL

Kolkata

18

AMTAS PRP (Amlodipine and Perindopril Tablets)

K2200008 2

01/2022

12/202

4

Intas Pharmaceuticals Ltd., Bhageykhola, Rangpo, East Sikkim -737132, India.

Assay of Perindopril Erbumine

CDSCO

East Zone Kolkata

CDL

Kolkata

19

Esylate (Etamsylate Injection 250 mg)

I-2359

12/2021

11/202

3

Jackson Laboratories Pvt. Ltd., Majitha Road, Amritsar 143001 (India).

Description, Particulate Matter & Extractable Volume

CDSCO

East Zone Kolkata

CDL

Kolkata

20

Montelukast Sodium and Levocetirizine Hydrochloride Tablets IP (Montzer-C)

MTZ2200 3

12/2022

11/202

4

Tirupati Medicare Limited, Nahan Road, Paonta Sahib, Distt. Sirmour (H.P.) 173 205.

Dissolution of Montelukast

CDSCO

East Zone Kolkata

CDL

Kolkata

21

Nicomode-2 (Nicoumalone Tablets IP 2 mg)

T222932

02/2023

01/202

5

United Bioceuticals Pvt. Ltd., Plot No. 33C, Industrial Park IV, Begumpur, Haridwar - 249402, Uttarakhand

Related Substances

CDSCO

East Zone Kolkata

CDL

Kolkata

22

Erythromycin Stearate Tablets (Enthrocin-500)

ATG3A04 8

01/2023

12/202

4

Anrose Pharma, 147, Mauza Sansiwala, P.O. Barotiwala, Tehsil Kasauli, Distt. Solan (H.P.).

Dissolution

CDSCO

East Zone Kolkata

CDL

Kolkata

23

Cefoperazone & Sulbactam for injection

S3A099

01/2023

12/202

4

Arion Healthcare, GMP Certified Company Vill. Kishanpura, Baddi, Distt. Solan 174 101 (H.P).

Assay of Sulbactam

CDSCO

Hyderabad

CDL

Kolkata

24

Doxycycline and Lactic Acid Bacillus Capsules(DOXORIA-L)

SOC- 2062A

11/2022

10/202

4

Symbiosis Pharmaceuticals Pvt. Ltd., At C/o Ovation Remedies, Behind IITT Engg. College, Trilokpur Road, Kala Amb- 173030 (Sirmour), HP

Assay /Content of Gram positive rod shaped spore forming bacteria

CDSCO

East Zone Kolkata

CDL

Kolkata

25

Amoxycillin Capsules IP 500 MG (AMOXYCILLIN

500)

C-5076

Oct- 2022

Sep- 2024

Jackson Laboratories Pvt.Ltd., 22-24, Majitha Road, Bye Pass, Amritsar-143 001

TEST FOR DISSOLUTION

CDSCO

Subzone Bangalore

CDTL

Chennai

26

Ciprofloxacin Hydrochloride Tablets IP 500 mg

0700323

Feb- 2023

Jan- 2025

Karnataka Antibiotics & Pharmaceuticals Limited, Plot No.14, II Phase, Peenya, Bangalore-560058.

TEST FOR DISSOLUTION

CDSCO

South Zone Chennai

CDTL

Chennai

27

Ofloxacin & Metronidazole Benzoate Suspension (VIVFLOX-MZ Suspension) (For Paediatric USE ONLY)

PFS-1204

Nov- 2022

Oct- 2024

Proceed Formulations, 17, Ind. Area, Morthikri,

Ramgarh-Derabassi Road,, Derabassi – 140 201.

ASSAY OF METRONIDAZOLE BENZOATE AND OFLOXACIN

CDSCO

South Zone Chennai

CDTL

Chennai

28

Metronidazole & Ofloxacin Suspension (nor-metrogyl o Suspension)

XSWN22 006

April- 2022

Mar- 2024

Hema Laboratories Pvt. Ltd. Plot No.29, Pharma City, Selaqui Industrial Area,

Dehradun – 248 011 (State Uttarakhand)

ASSAY OF METRONIDAZOLE BENZOATE AND OFLOXACIN

CDSCO

South Zone Chennai

CDTL

Chennai

29

Ibuprofen and Paracetamol Dispersible Tablets (Ibucon Plus Kid)

C211143 003

March- 2023

Feb- 2026

Concept Pharmaceuticals Ltd., A-28/3, MIDC,

Chikalthana, Aurangabad – 431 006

Diameter & Uniformity of Dispersion

CDSCO

West Zone Mumbai

CDTL

Mumbai

30

Calamine, Zinc Oxide, Aloe vera & Light Liquid Paraffin (Calmin Lotion)

C-012

Apr- 2022

March- 2025

Gladios Products Pvt Ltd., 31, Virat Industiral Estate, Dhanot, Gandhinagar, Gujarat – 382721

Specific gravity

CDSCO

Zonal Office

Ahmedaba d

CDTL

Mumbai

31

Lorazepam Tablets I.P. 2 mg

LZMT100 6

Feb- 2023

Jan- 2025

Unicure India Ltd., C-21, 22 & 23, Sector-3, Noida- 201301, Distt. : Gautam Budh Nagar (U.P.)

Dissolution and Assay

CDSCO

West Zone Mumbai

CDTL

Mumbai

32

Calcium and Vitamin D3 Tablets I.P.

KTB2176 AL

Nov - 2022

Apr- 2024

Karnataka Antibiotics & Pharmaceuticals Limited., Plot No.37, Site No.34/4, NTTF Main Road, 2nd Phase, Peenya Industrial

Area, Bengluru- 560058. At: Plot No. 5-9, Survey No.38/2,

Uniformity of content for Vitamin D3

CDSCO

West Zone Mumbai

CDTL

Mumbai

Aliyali Palghar (W), Dist. Palghar- 401404 (M.S).

33

Levocetirizine and Amrboxol Syrup (C & C Syrup)

BL23015

Feb- 2023

Jan- 2025

Baxil Pharma Pvt. Ltd., 10km, Nainital Highway, Shyampur, Haridwar 249408, Uttarakhand.

Assay of Ambroxol Hydrochloride

CDSCO

Ghaziabad

RDTL

Chandigarh

34

Povidone-Iodine Ointment USP 5% w/w

P1040

Aug- 2022

Jul- 2025

Babu Ram Om Prakash (BROP), Trilokpur Road, Ogli Village, Kala Amb,

Assay of Povidon Iodine calculated asAvailable Iodine

CDSCO

Ghaziabad

RDTL

Chandigarh

35

Cefpodoxime Proxetil for Oral Suspension IP

UCST- 2310

Mar- 2023

Feb- 2025

Ultra Drugs Pvt. Ltd., Manpura, Nalagarh, Distt.Solan-174101 (H.P.)

pH

CDSCO

Sub-Zone Jammu

RDTL

Chandigarh

36

Diclofenac Prolonged- Release Tablets IP 100 mg

CHT- 3037

Jan- 2023

Dec- 2024

Cotec Healthcare Pvt. Ltd., NH.No. 74, Roorkee- Dehradun Highway, Kishanpur, Roorkee-247667

(Uttarakhand)

Dissolution

CDSCO

Ghaziabad

RDTL

Chandigarh

37

Aspirin Gastro-resistant and Atorvastatin Capsules IP (75mg/10mg)

54CAT09

6

Sep- 2022

Aug- 2024

Swiss Garnier Life sciences, 21-23, Industrial Area, Mehatpur, Dist. Una, Himachal Pradesh- 174315.INDIA

Dissolution (buffer stage) of Aspirin and The Assay of Atrovastatin Calcium calculated as Atorvastatin

CDSCO

Ghaziabad

RDTL

Chandigarh

38

Mupirocin Ointment IP (MUPIJAI OINTMENT)

008

Sep- 2022

Aug- 2024

Baxil Pharma Pvt. Ltd., 10km, Nainital Highway, Shyampur, Haridwar 249408,

Assay of Mupirocin

Drug Control Departmen t Ghaziabad

RDTL

Chandigarh

39

The auto disable syringe (KOJAK SELINGE)

312053KJ M1

Mar- 2023

Feb- 2028

HINDUSTAN SYRINGES & MEDICAL DEVICES LTD., 174, 178/25, BALLABGARH, FARIDABAD, INDIA-121004

Design (Piston/Plunger Assembly) Fit of piston in barrel

CDSCO

Sub Zone Baddi

RDTL

Chandigarh

40

Rabeprazole Gastro- resistant Tablets IP (RABALKEM-20)

RBL2202 0RH

Oct- 2022

Sep- 2024

Ravian Life Science Pvt. Ltd., Plot No.34, Sector-8A, IIE, SIDCUL, Haridwar-249 403, Uttarakhand INDIA.

Dissolution

Drug Control Departmen t Assam

RDTL,

Guwahati

41

Paracetamol 120 mg + Chlorpheniramine Maleate 2 mg/ 5ml syrup (COLD OUT)

SF001A0 1

Jan- 2022

Dec- 2024

Fourrts (India) Laboratories Pvt. Ltd., Vandalur Road, Kelambakkam-603 103.

Tamil Nadu, INDIA.

Content of Ethylene Glycol 1.9%w/v & Diethylene Glycol 0.14%w/v

CDSCO,

South zone, Chennai

RDTL

Guwahati

42

Paracetamol 120 mg + Chlorpheniramine Maleate 2 mg/ 5 ml syrup (COLD OUT)

SF001B0 1

Feb- 2022

Jan- 2025

Fourrts (India) Laboratories Pvt. Ltd., Vandalur Road, Kelambakkam-603 103.

Tamil Nadu, INDIA.

Content of Ethylene Glycol 1.22%w/v

CDSCO,

South zone, Chennai

RDTL

Guwahati

43

Paracetamol 120 mg + Chlorpheniramine Maleate 2 mg/ 5 ml syrup (COLD OUT)

SF001A0 2

Jan- 2022

Dec- 2024

Fourrts (India) Laboratories Pvt. Ltd., Vandalur Road, Kelambakkam-603 103.

Tamil Nadu, INDIA.

Content of Ethylene Glycol 2.23%w/v& Diethylene Glycol 0.17%w/v

Drugs Inspector, CDSCO,

South

zone, Chennai

RDTL

Guwahati

44

CALCIUM ACETATE TABLETS USP 667 mg.,

(Lanum)

D222313

Jul-2022

Jun- 2025

STANDFORD LABORATORIES PRIVATE

LIMITED, 8, Industrial Area, Mehatpur, Dist. Una, H.P. - 174315

Assay

Drugs Inspector, Guwahati, Assam

RDTL

Guwahati

45

GENTAMYCIN INJECTION

I.P. (GENTAVIK 2ml.)

TGL0223 0318

Feb- 2023

Jan- 2025

T & G MEDICARE, Village- Kunjahal, P.O. Baddi, Distt. Solan (H.P.)

Sterillity and Bacterial Endotoxins Test

lnspector of Drugs, Arunachal Pradesh

RDTL

Guwahati

46

Pantoprazole Gastro Resistant Tablets I.P. (PAVE -40)

BBT2217 94

May - 2022

Apr- 2024

Biomax Biotechnics (P) Ltd., 261, HSIIDC, Industrial Estate, Alipur, Barwala- 134118 (Haryana)

Dissolution

Drugs Inspector, RAnchii,Jh arkhand

RDTL

Guwahati

47

Metformin Hydrochloride Prolonged Release and Glimepiride Tablets IP (GLIMESTAR® M2 FORTE)

P9IAV007

Nov- 2022

Oct 2024

MANKIND PHARMA LTD.

Doring Block, Bermiok Elaka, Dist. Namchi, Sikkim 737126

Disintegration and Dissoluton

Drugs Inspector, Mizoram

RDTL

Guwahati

48

COMPOUND SODIUM LACTATE INJECTION I.P.

03BF173

7

Aug- 2022

Jul- 2025

PASCHIM BANGA PHARMACEUTICAL, NH-31 TIN MILE HAT, SONAPUR HAT, P.S.-CHOPRA, DIST:

UTTAR DINAJPUR, PIN- 733214 (W.B.)

Bacterial Endoxtoxins Test

Drugs Inspector, AJZAWL,

Mizoram

RDTL

Guwahati

Also Read:Drug Alert: 51 Drug samples fail to qualify CDSCO test

Cuban Doctor Receives PAHO Award for Health Services Management and Leadership

Cristina Mitchell

26 Sep 2023